PTC Therapeutics has agreed a cash and shares deal to acquire Agilis Biotherapeutics , in a bid to expand its gene therapy portfolio . It focuses on gene therapy programmes that target rare central nervous system disorders , and is currently seeking FDA approval for its three most advanced therapies . Through the terms of the deal , it will pay $ 50 m in cash and a further $ 150 m in shares , and if Agilis wins FDA approval , it could receive a further $ 595 m .
PTC Therapeutics has agreed a cash and stock deal to acquire Agilis Biotherapeutics, in a bid to broaden its gene therapy portfolio. Agilis focuses on gene therapy programmes that target rare central nervous system disorders, and is currently seeking FDA approval for its three most advanced therapies. Through the terms of the acquisition, PTC will pay $50m in cash and a further $150m in shares, and if Agilis wins FDA approval, it could receive a further $595m.